CA 27-29 Test Results: Uses, Ranges and Limits

Klein, Thomas; Weber, Hans; Mitchell, Sarah

What the CA 27-29 Test Measures—and What It Cannot Prove

CA 27-29 measures circulating fragments of MUC1, a protein shed by some breast cancer cells, but it cannot confirm or exclude breast cancer on its own. In practice, clinicians use it selectively alongside symptoms, examination and imaging, usually when metastatic disease is already known.

The CA 27-29 test detects an epitope on MUC1, a large glycoprotein expressed on the surface of many epithelial cells. When MUC1 is released into circulation, an immunoassay reports a concentration in units per millilitre (U/mL); the number is a laboratory signal, not a map of where disease is located.

A normal CA 27-29 result does not rule out active breast cancer, because not every cancer releases measurable MUC1. Conversely, an elevated result does not establish malignancy; that asymmetry is the reason the test performs poorly as a screening tool in people without a prior cancer diagnosis.

I have seen a patient with stable scans and a CA 27-29 of 46 U/mL for more than 18 months, ultimately explained by chronic liver inflammation. The useful question was not “is 46 dangerous?” but whether it had moved meaningfully from her personal baseline of 43 to 46 U/mL; it had not. For related marker limitations, compare our explanation of the CA 15-3 result.

Why the name causes confusion

Despite the “CA” label, CA 27-29 is not a cancer diagnosis test. Cancer antigen describes the laboratory target, while clinical interpretation still requires pre-test probability, radiology and pathology.

CA 27-29 Normal Range: Why Your Lab’s Cutoff Wins

The CA 27-29 normal range is commonly below 38 U/mL, although some laboratories use an upper limit near 35 U/mL. The printed reference interval on your own report is more reliable than a universal internet cutoff because antibody reagents and calibration differ.

Most reports classify values below 38 U/mL as within range, 38 to 50 U/mL as a mild elevation, and values well above 50 U/mL as increasingly abnormal. These are practical bands rather than diagnostic stages, and a value of 37 U/mL is not biologically different from 39 U/mL.

The analytic variation of immunoassays means a small change may reflect assay noise rather than a true clinical shift. In my practice, a change of less than about 15% without new symptoms rarely changes management, particularly when samples come from different laboratories or different test methods.

Kantesti is an AI blood test analyzer that places CA 27-29 beside the laboratory’s stated range, prior values and related liver tests rather than treating an H flag as a diagnosis. A result flagged out of range deserves context; our guide to out-of-range lab flags explains why reference intervals are not treatment thresholds.

Within typical range <38 U/mL Does not rule out breast cancer and is interpreted against the individual baseline.

Mild elevation 38-50 U/mL Often prompts confirmation, review of benign causes and comparison with prior results.

Clear elevation 51-100 U/mL Needs clinical correlation, especially if rising on repeat testing.

Marked elevation >100 U/mL Can occur with substantial tumour burden or non-cancer illness; it is not an emergency value by itself.

When Oncologists Actually Use CA 27-29

CA 27-29 is most often ordered as an adjunct during treatment or surveillance of metastatic breast cancer when the marker was elevated at baseline. It is not routinely recommended for population screening or as a stand-alone recurrence test after early-stage treatment.

The 2007 ASCO tumour-marker guideline states that CA 27-29 and CA 15-3 may be used with imaging, history and physical examination to monitor metastatic disease, but not alone (Harris et al., 2007). The key condition is that the patient has measurable metastatic disease and that the marker has been informative for that individual.

For early-stage breast cancer, routine marker testing can create a difficult loop: a modestly high result triggers scans, scans find incidental changes, and anxiety rises without evidence that survival improves. ASCO’s metastatic biomarker guideline likewise advises clinicians not to change systemic treatment solely because a circulating marker rises (Van Poznak et al., 2015).

As of September 17, 2026, the most defensible use remains targeted, not automatic. Patients considering which routine tests have evidence behind them may find our article on cancer-risk blood test priorities helpful.

High CA 27-29 Causes Beyond Breast Cancer

High CA 27-29 causes include metastatic breast cancer, liver disease, pregnancy, endometriosis, benign ovarian conditions and several non-breast malignancies. A raised value has low specificity because MUC1-related proteins can increase when epithelial tissues are altered or clearance through the liver is impaired.

Benign hepatic conditions are among the most overlooked explanations for a raised CA 27-29 result. Cholestasis, hepatitis and cirrhosis may increase circulating MUC1 fragments or reduce clearance, so clinicians usually review ALT, AST, ALP, GGT and bilirubin before assuming cancer progression.

Pregnancy and some gynaecological conditions can also shift MUC1-associated assays. In a patient without known breast cancer, a CA 27-29 of 42 U/mL with normal examination and imaging has a very different meaning from a rise from 42 to 90 U/mL in a patient whose metastatic disease previously tracked with the marker.

Other malignancies, including lung, ovarian, pancreatic, colon and liver cancers, can elevate CA 27-29, but the test cannot identify which one is present. When liver tests are abnormal, start with the pattern in our cholestasis laboratory guide rather than assuming that the tumour marker explains it.

Why a CA 27-29 Trend Matters More Than One Result

A sustained CA 27-29 rise across two or more comparable samples is more useful than a single high measurement. Clinicians assess direction, rate of change, treatment timing and whether the change exceeds expected assay variation.

A practical rule is to repeat an unexpected isolated elevation before ordering extensive investigations, often after 2 to 6 weeks if the patient is clinically well. Repeating sooner than 7 days seldom clarifies a marker trend because biologic fluctuation and assay imprecision can dominate.

A relative increase of around 25% from a stable baseline is more attention-grabbing than a 2 U/mL difference near the upper limit, though no single percentage is universally validated for every assay. The rate matters: an increase from 28 to 56 U/mL over 3 months warrants a different discussion than 28 to 32 U/mL over 12 months.

Dr. Thomas Klein advises patients to save the date, laboratory name, treatment cycle and any intercurrent illness with every result. Those details make meaningful changes between blood tests much easier to separate from random variation.

What Clinicians Check Alongside a Rising Marker

A rising CA 27-29 result usually leads clinicians to check symptoms, examination findings, treatment adherence, liver tests and appropriate imaging—not to declare progression immediately. Imaging and the patient’s clinical state carry more weight than the marker alone.

New focal bone pain, unexplained weight loss, persistent cough, breathlessness, abdominal fullness, jaundice or neurologic symptoms shift the urgency of assessment. A normal CA 27-29 result does not neutralise these symptoms, particularly because some metastatic cancers do not produce this marker at all.

If there is no obvious clinical explanation, the oncology team may compare CT, PET-CT, bone imaging or targeted ultrasound with prior studies. The 2021 ESMO early breast cancer guideline does not support routine imaging or tumour-marker surveillance in asymptomatic survivors because false positives can lead to harm without proven outcome benefit (Cardoso et al., 2021).

The reason we worry about marker rise plus ALP elevation and deep bone pain is that the combination can support targeted skeletal assessment, whereas any one of those findings alone is often nonspecific. For a careful explanation of marker patterns after therapy, see rising tumour markers after treatment.

CA 27-29 During Treatment: Early Changes Can Mislead

CA 27-29 can rise transiently during the first 4 to 6 weeks of effective systemic therapy, so an early increase should not automatically trigger a treatment change. Clinicians usually confirm the pattern with symptoms, examination and scheduled imaging.

Marker release from affected cells and delayed clearance can produce a temporary “flare” after treatment begins. This is one reason ASCO recommends caution during the initial 4 to 6 weeks of a new therapy; stopping a regimen too early can deprive a patient of an effective option.

Later in treatment, a fall of 30% to 50% can be reassuring when symptoms and imaging improve, but it does not prove that all disease has resolved. I have seen imaging improve while CA 27-29 stayed nearly flat because that patient’s cancer simply did not shed much MUC1.

Kantesti AI is an AI blood test interpretation platform that can organise dates and serial values for clinician discussion, but it does not replace oncology imaging or direct treatment advice. Our longitudinal lab review guide explains the value of building a personal baseline.

Why Different Laboratories Can Give Different CA 27-29 Values

CA 27-29 results from different assay systems may not be numerically interchangeable, even when both laboratories use U/mL. For monitoring, the safest approach is to use the same laboratory and method whenever possible.

CA 27-29 assays use antibodies that recognise MUC1-related epitopes, yet antibody design, calibrators and signal detection vary by manufacturer. A shift from 31 U/mL at one laboratory to 43 U/mL at another can be a method difference rather than a biologic increase.

Laboratories may also flag a sample for interference when heterophile antibodies or unusual sample factors distort immunoassays. This is uncommon, but a result that sharply contradicts a stable patient and stable scans deserves laboratory review, repeat testing or an alternate analytical method.

Before uploading a report, verify the date, units, test name and reference range; a transcription error can look like a biologic crisis. Our PDF upload accuracy checklist covers the small report details that can alter interpretation.

CA 27-29 Versus CA 15-3: Similar Biology, Not Extra Certainty

CA 27-29 and CA 15-3 are both MUC1-related breast cancer markers, so ordering both rarely provides twice the information. Most oncology teams choose the marker that was elevated and reproducible at that patient’s baseline.

CA 15-3 and CA 27-29 detect different epitopes on the same broad MUC1 protein family. Their results may track together, but discordance is possible because one epitope can be shed or detected differently from another.

Using both markers can sometimes clarify an unusual result, but it can also double the chance of a false-positive signal. A marker that was normal when metastatic disease was documented is a poor tool for monitoring that individual, whatever its theoretical sensitivity.

The choice is a clinical workflow decision, not a contest between tests. Readers comparing marker roles can review our CA 19-9 interpretation guide for another example of why tumour markers are context-dependent.

Why CA 27-29 Cannot Screen for Breast Cancer Recurrence

CA 27-29 cannot reliably screen for breast cancer recurrence because it misses many recurrences and generates false alarms in people without recurrence. A test must be both sensitive and specific to work as a screening strategy, and CA 27-29 does not meet that standard.

A surveillance blood test sounds appealing, especially after treatment, but early detection only helps when it changes outcomes. Repeated CA 27-29 testing in asymptomatic early-stage survivors has not shown enough benefit to outweigh unnecessary scans, incidental findings and anxiety.

Mammography remains the standard imaging tool for surveillance of remaining breast tissue after appropriate treatment, while the follow-up schedule depends on surgery, radiation, symptoms and oncology advice. A marker result cannot substitute for scheduled imaging, genetic-risk assessment or a new examination finding.

This is one of those areas where context matters more than the number. For patients with persistent tenderness or a new change, our breast symptom testing overview explains why blood tests have a limited diagnostic role.

What to Do After a High CA 27-29 Result

After a high CA 27-29 result, first confirm the laboratory range, compare prior results and contact the clinician who ordered the test. Do not self-diagnose cancer or alter oncology medication on the basis of one measurement.

Bring three facts to the appointment: the exact value and range, at least two prior values with dates, and new symptoms since the previous test. Also list recent infections, pregnancy status, liver conditions, new supplements and medication changes, because these can shape the differential.

A modest first elevation may be repeated in 2 to 6 weeks, often at the same laboratory, while marked or rapidly rising values may prompt earlier oncologic review. If jaundice, severe breathlessness, confusion, new weakness, uncontrolled pain or a severe headache occurs, seek urgent care based on symptoms rather than waiting for another marker.

Kantesti is an AI-powered blood test analysis tool designed to make report context and trends easier to discuss with a clinician; it is not a cancer diagnostic service. Our doctor-visit lab summary checklist can help organise focused questions.

The Liver-Test Pattern That Can Change Interpretation

Abnormal liver tests can make a high CA 27-29 result less specific, especially when ALP, GGT or bilirubin are elevated. The pattern of liver abnormalities helps distinguish hepatocellular injury, cholestasis and non-hepatic explanations.

An ALT-predominant pattern often points toward hepatocellular injury, whereas disproportionately high ALP and GGT suggest cholestasis or bile-duct involvement. Neither pattern diagnoses cancer, but both can explain why an epithelial marker is unexpectedly elevated.

Bilirubin above the laboratory upper limit with dark urine, pale stool or itching deserves prompt clinical review regardless of CA 27-29. In our clinical work, the marker becomes secondary when the liver pattern itself indicates possible obstruction, acute hepatitis or medication toxicity.

Kantesti AI compares a marker with liver-panel context and flags combinations for clinical follow-up rather than using one abnormal result in isolation. For the underlying tests, see our guide to what a liver panel includes.

Seven Useful Questions to Ask Your Oncology Team

The most useful CA 27-29 questions are whether the marker was elevated at baseline, whether the same assay was used, and what action a further rise would change. These questions turn a confusing number into a shared monitoring plan.

Ask: “Was CA 27-29 a reliable marker for my cancer when disease was visible?” If the answer is no, repeated testing may provide more anxiety than useful information. Ask also whether the current change exceeds assay and biologic variation, often roughly 15% to 20% for small shifts.

Ask what symptoms should trigger an earlier call, what imaging is planned, and whether liver or kidney changes could influence the result. A good answer should name the next decision point—for example, repeat testing in 4 weeks, scan at 12 weeks, or assessment sooner if symptoms develop.

Dr. Thomas Klein recommends writing these questions down before the appointment; it is easy to lose them when a report arrives. Our medical advisory board supports the clinical-review principles behind Kantesti educational content.

How Kantesti Places CA 27-29 in Laboratory Context

Kantesti interprets CA 27-29 as a contextual monitoring marker by checking the reported range, serial movement and related laboratory findings. Our analysis is designed to support informed follow-up, not to diagnose cancer or recommend cancer treatment.

Kantesti AI reads uploaded laboratory reports and can surface a change such as 29 to 47 U/mL alongside the draw dates, the laboratory range and related markers. It cannot see a patient’s scan images, physical examination or pathology, which is precisely why oncology interpretation must remain clinician-led.

A high-quality interpretation separates analytic significance from clinical significance. For example, a 12 U/mL increase may be notable if it is a 50% rise from baseline, while a 12 U/mL difference may be minor if different laboratories and assay methods were used.

Our methodology is reviewed against clinical safety standards described in the technical validation overview, and our AI technology guide explains how contextual result extraction works. Keep the original report, involve the ordering clinician and treat urgent symptoms as urgent.

The Bottom Line on CA 27-29 Results

CA 27-29 is a selective monitoring aid for some patients with known metastatic breast cancer, not a screening or diagnostic test. A persistent, assay-consistent rise can support further assessment, but symptoms and imaging determine what the result means.

A result below 38 U/mL is often reported as within range, but neither a normal nor high value can settle the question of cancer by itself. The clinically useful signal is a confirmed trend that matches the patient’s known disease pattern and other evidence.

Most patients find it helpful to replace “What does this number mean?” with “What does this number change?” If the answer is “nothing yet,” a repeat at the same laboratory and attention to symptoms may be safer than immediate conclusions.

Kantesti provides educational result context for people in more than 127 countries, while oncology teams remain responsible for diagnosis and treatment decisions. For broader reference intervals and test definitions, use our blood biomarker reference guide.

Frequently Asked Questions

What is a normal CA 27-29 level?

A CA 27-29 level below 38 U/mL is within the reference range at many laboratories, although some laboratories use an upper limit near 35 U/mL. The reference interval printed on your own report is the correct one to use because assay methods differ. A result within range does not rule out breast cancer, and a result above range does not diagnose breast cancer. For monitoring, a patient’s serial baseline is often more informative than a single value.

Does a high CA 27-29 mean breast cancer has returned?

A high CA 27-29 level does not by itself mean breast cancer has returned or progressed. Levels above 38 U/mL can occur with liver disease, pregnancy, endometriosis, benign ovarian conditions and cancers other than breast cancer. In someone with known metastatic breast cancer, a confirmed increase of about 25% or more across comparable tests may lead an oncology team to review symptoms and imaging. Treatment should not be changed solely because CA 27-29 rises.

How high is CA 27-29 in metastatic breast cancer?

CA 27-29 can be normal, mildly elevated or markedly elevated in metastatic breast cancer because MUC1 shedding differs widely between cancers. Values above 100 U/mL can occur with substantial disease burden, but this level is not diagnostic and does not identify the disease location. Some people with confirmed metastatic disease remain below 38 U/mL throughout their illness. The change from that person’s own baseline is more useful than comparing one number with another patient’s result.

Can liver disease raise CA 27-29?

Yes, liver disease can raise CA 27-29 and is a common non-cancer explanation for an unexpected result. Hepatitis, cirrhosis and cholestatic patterns with elevated ALP, GGT or bilirubin may alter MUC1-related marker levels or their clearance. A CA 27-29 result of 45 U/mL with abnormal liver tests needs a different interpretation from the same value with normal liver tests and a known marker-producing cancer. Clinicians usually review the liver panel before attributing a rise to cancer progression.

How often should CA 27-29 be repeated?

CA 27-29 repeat timing depends on the reason for testing, treatment schedule and symptoms. An unexpected mild elevation in a clinically well patient is often repeated after about 2 to 6 weeks, ideally at the same laboratory. During active metastatic treatment, oncology teams may test every 1 to 3 months when the marker previously tracked with disease. Repeating an isolated result within a few days rarely provides a clinically reliable trend.

Is CA 27-29 better than CA 15-3?

CA 27-29 is not clearly better than CA 15-3 because both are MUC1-related markers used as adjuncts in metastatic breast cancer monitoring. The tests recognise different MUC1 epitopes, so one may be more informative in a particular patient, but ordering both does not automatically improve care. Oncology teams usually follow the marker that was elevated and reproducible when disease was known to be present. Neither test can diagnose breast cancer or replace imaging.

CA 27-29 Test Results: Uses, Ranges and Limits

Thomas Klein, MD

Sarah Mitchell, MD, PhD

Prof. Dr. Hans Weber, PhD